ASH 2022 | Outcomes of patients with CLL infected by COVID-19 between 2020 and 2022
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, comments on the findings of a study analyzing the outcomes of patients with chronic lymphocytic leukemia (CLL) who were infected with COVID-19 between 2020 and 2022. Overall, it was found that there was an improvement in life expectancy from 2020 to 2022 due to better COVID-19 management strategies and a higher vaccination rate. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MSD: Consultancy, Honoraria; Roche: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Lilly/Loxo: Consultancy, Honoraria.
